Telephone:
(925) 558-5040
en
Crystallization is a critical step in small molecule drug development, directly impacting API purity, solid form, particle properties, and manufacturability. A well-designed crystallization process ensures consistent production of the target form while enabling scalable, cost-effective manufacturing from early development through commercialization.
Crystallization defines the final quality attributes of an API — including polymorphic form, impurity profile, particle size distribution, and downstream processability. Poorly designed crystallization processes can introduce variability, compromise impurity control, and create significant challenges during scale-up. Without a robust strategy, these risks often lead to late-stage process changes, delays, and increased manufacturing costs.
A structured crystallization development approach ensures consistent API performance while reducing technical and regulatory risk.
Crystallization development supports API progression from early material supply through commercial manufacturing. Early-stage work focuses on rapid process design and material generation, while later stages emphasize process optimization, robustness, and readiness for scale-up and regulatory submission.
Effective crystallization development is grounded in a deep understanding of the solid-state landscape and its relationship to process conditions. By integrating solid form screening, phase behavior analysis, and solubility profiling, crystallization processes can be rationally designed to control form selection and transformation pathways.
This approach enables precise control over critical attributes such as polymorphic form, crystal habit, and impurity incorporation — ensuring that process conditions consistently deliver the intended material properties.
Crystallization processes are developed with scalability as a core objective, ensuring a seamless transition from laboratory development to GMP manufacturing. Process design focuses on robustness, reproducibility, and compatibility with downstream operations including filtration, drying, and material handling.
Process robustness and reproducibility across scales
Control strategy for critical process parameters (CPPs) and critical quality attributes (CQAs)
Compatibility with large-scale manufacturing operations and downstream processing
Consistent production of the target crystal form
Improved impurity control and API purity
Optimized yield and process efficiency
Controlled particle size and morphology
Reduced risk of late-stage form changes
Scalable and reproducible manufacturing processes
Subscribe to be the first to get the updates!